Adar1 Capital Management, LLC Biotechnology

Adar1 Capital Management, LLC

$615 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$33B	$59.6 Million 0.01% of portfolio	110	Q3 2024 New
AXSM Axsome Therapeutics, Inc.	$4.21B	$53.9 Million 0.01% of portfolio	600	Q3 2024 Added 100.0%
CARA Cara Therapeutics, Inc.	$16.7M	$49.1 Million 0.01% of portfolio	159,469	Q2 2024 New
ETNB 89bio, Inc.	$387M	$48.5 Million 0.01% of portfolio	6,560	Q3 2024 Added 17.99%
FGEN Fibrogen Inc	$36.6M	$48.2 Million 0.01% of portfolio	120,663	Q3 2024 New
CELC Celcuity Inc.	$190M	$44.7 Million 0.01% of portfolio	3,000	Q3 2024 Added 114.29%
OVID Ovid Therapeutics Inc.	$74.6M	$44.5 Million 0.01% of portfolio	37,743	Q3 2024 Added 96.68%
ARDX Ardelyx, Inc.	$796M	$44.1 Million 0.01% of portfolio	6,400	Q3 2024 Reduced 90.86%
MIST Milestone Pharmaceuticals Inc.	$55.5M	$42.5 Million 0.01% of portfolio	27,931	Q3 2024 Reduced 86.2%
MREO Mereo Biopharma Group PLC	$460M	$41.1 Million 0.01% of portfolio	10,000	Q3 2024 Reduced 81.95%
VERU Veru Inc.	$50.5M	$39.2 Million 0.01% of portfolio	51,000	Q3 2024 New
LUMO Lumos Pharma, Inc.	$36.3M	$38.7 Million 0.01% of portfolio	10,000	Q3 2024 New
PHVS Pharvaris N.V.	$710M	$37 Million 0.01% of portfolio	2,000	Q1 2024 New
PYXS Pyxis Oncology, Inc.	$69.8M	$36.7 Million 0.01% of portfolio	10,000	Q1 2024 New
IDYA Ideaya Biosciences, Inc.	$1.28B	$31.7 Million 0.01% of portfolio	1,000	Q3 2024 Added 233.33%
IONS Ionis Pharmaceuticals Inc	$4.82B	$28 Million 0.0% of portfolio	700	Q3 2024 Reduced 53.33%
RNA Avidity Biosciences, Inc.	$2.22B	$27.6 Million 0.0% of portfolio	600	Q3 2024 New
KRYS Krystal Biotech, Inc.	$4.68B	$18.2 Million 0.0% of portfolio	100	Q3 2024 New
NTLA Intellia Therapeutics, Inc.	$1.05B	$16.4 Million 0.0% of portfolio	800	Q3 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$285M	$16 Million 0.0% of portfolio	2,000	Q3 2024 New
RLYB Rallybio Corp	$31.8M	$15.6 Million 0.0% of portfolio	13,300	Q3 2024 Added 18.75%
RAPT Rapt Therapeutics, Inc.	$31.1M	$15.1 Million 0.0% of portfolio	7,500	Q2 2024 New
DYN Dyne Therapeutics, Inc.	$1.54B	$14.4 Million 0.0% of portfolio	400	Q3 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.63B	$10.6 Million 0.0% of portfolio	50	Q3 2024 New
GLYC Glycomimetics Inc	$16.3M	$7.72 Million 0.0% of portfolio	45,700	Q3 2024 Reduced 66.15%
EQ Equillium, Inc.	$23.4M	$6.09 Million 0.0% of portfolio	7,318	Q3 2024 Reduced 94.8%
MRVI Maravai Lifesciences Holdings, Inc.	$652M	$5.82 Million 0.0% of portfolio	700	Q3 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$370M	$3.62 Million 0.0% of portfolio	200	Q3 2024 New
SWTX Spring Works Therapeutics, Inc.	$2.27B	$3.2 Million 0.0% of portfolio	100	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.